Stockscreener 앱 받기
2.04
4.23%
-0.09
시간 외 거래:
2.07
0.03
+1.47%
전일 마감가:
$2.13
열려 있는:
$2.13
하루 거래량:
6.73M
Relative Volume:
0.77
시가총액:
$615.89M
수익:
$188.87M
순이익/손실:
$-400.38M
주가수익비율:
-1.36
EPS:
-1.5
순현금흐름:
$-260.90M
1주 성능:
+9.09%
1개월 성능:
-12.07%
6개월 성능:
+36.00%
1년 성능:
-2.86%
1일 변동 폭
$1.98
$2.13
1주일 범위
$1.79
$2.22
52주 변동 폭
$0.8511
$2.725
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
2.04 | 643.06M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
126.18 | 220.91B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.38 | 146.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.21 | 140.64B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.69 | 127.91B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.58 | 49.23B | 5.88B | 1.34B | 799.60M | 2.3489 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-04-18 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
What technical charts say about Pacific Biosciences of California Inc. stockJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - ulpravda.ru
Can Pacific Biosciences of California Inc. stock double in next 5 yearsJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - ulpravda.ru
Can Pacific Biosciences of California Inc. stock deliver consistent earnings growthDividend Hike & Verified Momentum Watchlists - ulpravda.ru
PacBio introduces CiFi method for chromosome-scale genome assembly By Investing.com - Investing.com Canada
PacBio Introduces CiFi: A Breakthrough Method for Chromosome-Scale Genome Assemblies from Limited Sample Material - Quiver Quantitative
PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell - MarketScreener
Will Pacific Biosciences of California Inc. (P09) stock justify high valuationFed Meeting & Expert Curated Trade Ideas - ulpravda.ru
Pacific Biosciences of California (PACB) Gains As Market Dips: What You Should Know - sharewise.com
Here's Why You Should Add PacBio Stock to Your Portfolio - Yahoo Finance
PACB (Pacific Biosciences of California) Land And Improveme - GuruFocus
What analysts say about Pacific Biosciences of California Inc stockOptions Trading Strategies & Low Entry Cost Trading - earlytimes.in
Three Genomics Stocks Worth Tracking This Year - Nasdaq
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt - simplywall.st
Barclays analyst is bullish on Pacific Biosciences of California, Inc. (PACB) - MSN
What drives Pacific Biosciences of California Inc P09 stock priceMarket Volatility Update & Missed Nvidia? Don’t Miss This One - earlytimes.in
Retail Surge: Will Pacific Biosciences of California Inc P09 stock rise with strong economyJuly 2025 Volume & Low Risk Entry Point Tips - moha.gov.vn
Stocks making big moves this week: PacBio, Crocs, FuelCell Energy, AMC Entertainment, and ON24 - The Globe and Mail
PacBio (PACB) Stock Is Up, What You Need To Know - Finviz
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap UpTime to Buy? - MarketBeat
What analysts say about Pacific Biosciences of California Inc P09 stockTechnical Resistance Breaks & Outstanding Capital Returns - earlytimes.in
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio - The Globe and Mail
Why Is PacBio (PACB) Stock Soaring Today - Finviz
Cathie Wood’s Strategic Move: ARK Investment Buys PacBio Shares - StocksToTrade
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 7.1%Should You Buy? - MarketBeat
Cathie Wood’s ARK Investment Fuels PacBio Stock Surge - timothysykes.com
Barclays Analyst Is Bullish On Pacific Biosciences of California, Inc. (PACB) - Finviz
PacBio to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
How to watch PacBio’s J.P. Morgan Healthcare Conference webcast - Stock Titan
12 Best Genomics Stocks to Invest In - Insider Monkey
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 5.1%What's Next? - MarketBeat
Cathie Wood’s ARK buys Weride, Pacific Biosciences stocks, sells Ibotta By Investing.com - Investing.com Nigeria
ARK Investment Acquires Additional Shares of PacBio (PACB) - GuruFocus
Cathie Wood’s ARK buys Weride, Pacific Biosciences stocks, sells Ibotta - Investing.com
ARK Investment Acquires Significant Stake in PacBio (PACB) - GuruFocus
Pacific Biosciences unveils gift campaign with coffee subscription giveaway - Traders Union
Pacific Biosciences of California Target of Unusually Large Options Trading (NASDAQ:PACB) - MarketBeat
Will Pacific Biosciences of California Inc. stock maintain dividend yieldJuly 2025 Decliners & Fast Moving Stock Watchlists - Улправда
Is Pacific Biosciences of California Inc. (P09) stock ideal for retirement investorsMarket Growth Review & Technical Entry and Exit Tips - ulpravda.ru
How Pacific Biosciences of California Inc. stock valuations compare to rivalsInsider Selling & Long-Term Investment Growth Plans - Улправда
Pacific Biosciences of California (HAM:P09) EV-to-OCF : -7.32 (As of Dec. 20, 2025) - GuruFocus
What insider trading reveals about Pacific Biosciences of California Inc. stockQuarterly Portfolio Review & Weekly High Return Forecasts - Улправда
Aug Mood: What insider trading reveals about Pacific Biosciences of California Inc. stock - Улправда
How Pacific Biosciences of California Inc. stock reacts to Fed rate cutsPortfolio Growth Summary & Free Safe Entry Trade Signal Reports - DonanımHaber
Is Pacific Biosciences of California Inc. stock a defensive play in 2025GDP Growth & Weekly High Momentum Picks - Улправда
Highs Report: Is Pacific Biosciences of California Inc. stock a defensive play in 2025 - ulpravda.ru
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.10%
0.57%
자본화:
|
볼륨(24시간):